Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Omitting bolus 5 ...
Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. This is ...
The approval was based on data from the KEYNOTE-590 study, which evaluated pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy vs placebo plus cisplatin and 5-FU chemotherapy as ...
NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with ...
Colorectal cancer remains the second commonest cause of cancer death in Western Europe and North America. Overall survival is poor; even in those patients who undergo potentially curative resection, ...
New research has identified that the frequently used chemotherapy drug (5-FU or Fluorouracil) is 100 per cent more effective at targeting tumors (rather than surrounding tissues) when administered ...
Australian researchers have unlocked the mystery as to why the chemotherapy drug 5-Fluorouracil (5-FU) is not effective at treating certain cancers and have claimed a breakthrough in boosting its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback